Skip to content
Agentic OS
Menu

Intelligence / Healthtech / New Clinical Trials / Shanghai Qilu Pharmaceutical Research and Development Center LTD

Clinicaltrial registered16 Nov 2026

Shanghai Qilu Pharmaceutical Research and Development Center LTD

16 Nov 2026: Trial registered · A Phase I Study to Evaluate Single and Multiple Subcutaneous Administrations of QLS2406-1 Injection in Chinese Adult Participants With Overweight and Obesity.. Recorded in the ClinicalTrials.gov (US National Library of Medicine).

View the source record

Posted
16 Nov 2026
Title
A Phase I Study to Evaluate Single and Multiple Subcutaneous Administrations of QLS2406-1 Injection in Chinese Adult Participants With Overweight and Obesity.
Conditions
Overweight and Obesity, MASH - Metabolic Dysfunction-Associated Steatohepatitis
Phase
Phase 1
Study Type
Interventional
Status
Not Yet Recruiting
Reference
NCT07937787
What this signal means

A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.

  1. United States leads with 192 of 777, then China (171).
  2. 777 added in the 30 days to 18 Nov 2026.
Reach them with AOS

Find the decision makers at Shanghai Qilu Pharmaceutical Research and Development Center LTD

AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.

Start free

Across AOS Research

Other records for Shanghai Qilu Pharmaceutical Research and Development Center LTD in our registers.

Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.